Professor Ira Jacobson Official Opening ACADEMIC SPONSOR:
|
|
- Claude Howard
- 7 years ago
- Views:
Transcription
1 Professor Ira Jacobson Official Opening ACADEMIC SPONSOR:
2 Welcome to Frankfurt and The Viral Hepatitis Congress
3 Development of the Congress In 2010 we recognised a high volume of compounds for HCV that might reach the market by 2016 Developments are occurring at a rapid pace Based on the success of the HIV Congress (this November will be the 11th meeting since the congress was initiated in 1990) a forum for clinicians and investigators to assimilate complex information in a rapidly developing field with an increasing array of treatment options The Scientific Committee, co-chaired by myself and Professor Stefan Zeuzem under the auspices of Weill Cornell Medical College and Goethe Universität, has collaborated on ideas and topics to develop a relevant and exciting Scientific Programme
4 Joint Academic Sponsors
5 The Viral Hepatitis Congress Scientific Committee Scientific Committee Chairs Ira Jacobson Weill Cornell Medical College, New York, USA Stefan Zeuzem J.W. Goethe University, Frankfurt, Germany Scientific Committee Nezam Afdhal Harvard Medical School, Boston, USA Antonio Craxì University of Palermo, Palermo, Italy Geoffrey Dusheiko Royal Free Hospital and University College School of Medicine, London, UK Graham Foster Queen Mary, University of London, London, UK Patrick Marcellin University of Paris, Paris, France Hendrik Reesink Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands Jürgen Rockstroh University of Bonn, Bonn, Germany
6 The Journey So Far
7 HCV Key Developments Interferon alfa Ribavirin Peginterferons Telaprevir & boceprevir Cure of HCV without IFN IL28B HCV identified Replicon developed Infectious virus 2a Description of non-a, non-b hepatitis Genome organization & processing determined Infectious clone developed Adaptive mutations identified Humanized mouse models established Adapted from Dr J Lemm
8 HBV Key Developments Adefovir Tenofovir Blood bank screening Genome sequenced Interferon alfa Lamivudine Entecavir, PEG- IFN2a Long term data on oral antivirals Discovery of Australia antigen (HBsAg) e antigen discovered HBV particle discovered by electron microscopy Plasma vaccine Recombinant vaccine Universal immunization of infants Telbivudine
9 The Viral Hepatitis Congress: Our Aim Continued innovation and progress results in a wealth of new information. We aim to: Provide you with a concise update on new advances in viral hepatitis To focus on practical guidance: what the new scientific developments mean for the present and the future clinical management of viral hepatitis
10 Meeting Format The Scientific Programme is built around a core format of plenary sessions, so you will never miss out on the latest information This afternoon there will be two Keynote Lectures on the hepatitis B and C viruses and over the next couple of days you will have the opportunity to listen to a world renowned faculty covering a wide range of topics Interaction is encouraged; tomorrow there are panel discussions and on Sunday we have a very busy agenda but there will still be opportunities to ask questions via cards and from the floor Please visit the scientific posters that will be displayed for the duration of the congress in the Casino building
11 Our Programme for Today Official Opening I. Jacobson (USA) S. Zeuzem (Germany), Key Note Lecture: Hepatitis C Virus R. Bartenschlager (Germany) Key Note Lecture: Hepatitis B Virus B. McMahon (USA)
12 We Welcome Your Participation Question cards and standing microphones are provided Please fill in the question cards during the presentation and pass to a staff member If you wish to ask a question or raise a point during the Q&A sessions, please make your way to one of the standing microphones
13 Thank you to our sponsors
14 And finally Please turn off your mobile phone This meeting has been granted 13 CME credits by the European Accreditation Council for Continuing Medical Education (EACCME). To obtain your CME credits, you must sign the register on the Congress General Information Desk on a daily basis More information on CME credits can be found in your Final Programme Booklet
THE VIRAL HEPATITIS CONGRESS 2015. 10 12 September 2015, Kap Europa, Frankfurt, Germany THE VIRAL HEPATITIS CONGRESS. Scientific Programme
THE VIRAL HEPATITIS CONGRESS THE VIRAL HEPATITIS CONGRESS 2015 10 12 September 2015, Kap Europa, Frankfurt, Germany Scientific Programme PRE-CONGRESS WORKSHOP SPONSOR ACHILLION Achillion is seeking to
More informationBriefing Note: Hepatitis B & Hepatitis C. Summary:
Briefing Note: Hepatitis B & Hepatitis C Summary: In Canada, hepatitis B and hepatitis C infections remain serious public health concerns due to high prevalence rates, high health care expenditures and
More informationHepatitis C treatment update
Hepatitis C treatment update Viral Hepatitis Workshop Hepatitis Foundation and Regional Public Health December 2013 Jeffrey S Wong Hepatitis C treatment Non-A non-b hepatitis History of HCV treatment Hutt
More informationAdefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B. Issue date: February 2006
Issue date: February 2006 Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic Understanding NICE guidance information for people with chronic, their families and carers, and the public
More informationHEPATITIS COINFECTIONS
HEPATITIS COINFECTIONS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures (Activity w/i 12 months)
More informationTwenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones
Twenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones Twenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones 3 Executive Summary 4 Introduction 5 The
More informationDr. Abonyi Margit PhD SE 1st Medical Clinic Associate Professor. Hepatology-2014
Dr. Abonyi Margit PhD SE 1st Medical Clinic Associate Professor Hepatology-2014 Other virus hepatitis Epstein-Barr vírus Cytomegalo vírus Herpes simplex vírus Coxsackie vírus Hepatitis B vírus Hepadnavírus,
More informationRobert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012
Treatment of Hepatitis C:Present and Future Robert G. Knodell, M.D. Scientific Meeting Maryland Chapter, American College of Physicians Fb February 3, 2012 Presentation Objectives Appreciate the Public
More informationDE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME
DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME Johan Neyts Rega Institute for Medical Research, University of Leuven, Belgium Johan.neyts@rega.kuleuven.be www.antivirals.be Pentalfa, 28
More informationHIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
More informationUPDATE ON NEW HEPATITIS C MEDICINES
UPDATE ON NEW HEPATITIS C MEDICINES Diana Sylvestre, MD 2014 AASLD/IDSA Guidelines: Gt 1 Treatment naïve Interferon eligible: sofosuvir + ribavirin + PEG-IFN x 12 weeks Interferon ineligible: sofosbuvir
More informationManagement of Chronic Hepatitis B: 2012 Update
Management of Chronic Hepatitis B: 2012 Update Brian J McMahon MD, Liver Disease and Hepatitis Program Alaska Native Medical Center and Arctic Investigations Program, CDC Conflicts of Interest The Liver
More informationHEPATITIS B VIRUS (HBV) & HEPATITIS C VIRUS (HCV)
HEPATITIS B VIRUS (HBV) & HEPATITIS C VIRUS (HCV) PATHOGEN SAFETY DATA SHEETS - INFECTIOUS SUBSTANCES INFECTIOUS AGENT NAME: Hepatitis B virus (HBV). SYNONYM OR CROSS REFERENCE: HBV, hepatitis B, HBV infection,
More informationHCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening
More informationHepatitis C Class Review
Hepatitis C Class Review Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January
More informationWhen an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)
XI. OCCUPATIONAL EXPOSURES TO HEPATITIS B AND C RECOMMENDATION: When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) The risk of transmission
More informationPURPOSE: To define the criteria to be used to determine the medical necessity of antiviral therapy in the treatment of Chronic Hepatitis B.
COVENTRY Health Care Guidelines for Hepatitis B Therapy SUBJECT: Chronic Hepatitis B Therapy: a. Interferons - Intron A (interferon alfa-2b) and Pegasys (peginterferon alfa-2a) b. Nucleoside analogues
More informationMarketVIEW: Hepatitis C Virus (HCV) vaccines (CAT: VAMV042) Background. ****Published February 2013***
****Published February 2013*** MarketVIEW: Hepatitis C Virus (HCV) vaccines (CAT: VAMV042) Product Name : MarketVIEW: Hepatitis C Virus (HCV) vaccines Description : Global vaccine commercial opportunity
More informationInnovazione farmacologica e farmacologia clinica
Innovazione farmacologica e farmacologia clinica Francesco Scaglione, MD, PhD Department of Medical Biotechnology and Translational Medicine School of medicine Postgradute School of clinical pharmacology
More informationFirst Announcement. 2 6 November 2014 Scottish Exhibition and Conference Centre Glasgow, UK. Joint Academic Sponsors
2 6 November 2014 Scottish Exhibition and Conference Centre Glasgow, UK First Announcement Joint Academic Sponsors University College London Medical School (UCLMS), UK Karolinska Institutet Stockholm Sweden
More informationHepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas
Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Virus Shimizu et al., 1996 Positive single strand RNA virus Flaviviridae family, Hepacivirus genus 9.6 kbp genome ~3000
More informationHepatitis C Treatment Advocacy: Ireland. Brian O Mahony
Hepatitis C Treatment Advocacy: Ireland Brian O Mahony Haemophilia and Hepatitis C 775 people with Haemophilia in Ireland 252 people with Haemophilia infected with Hepatitis C before 1992 106 of these
More informationFederal Government Standing Committee on Health
Federal Government Standing Committee on Health Inquiry into Hepatitis C in Australia Professor Gregory Dore Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Australia Infectious
More informationVirology. Behandlung der Hepatitis B. HBV Genome. HBV life cycle. HBV Genotypes. Natural History. 8 genotypes: A, B, C, D, E, F, G, H
Virology Behandlung der Hepatitis B Markus Heim Universitätsspital Basel 1 2 HBV Genome HBV life cycle 3 4 HBV Genotypes Natural History 8 genotypes: A, B, C, D, E, F, G, H genotypes A and D are prevalent
More informationNewly Diagnosed: HEPATITIS C. American Liver Foundation Support Guide
Newly Diagnosed: HEPATITIS C American Liver Foundation Support Guide T he American Liver Foundation's mission is to facilitate, advocate, and promote education, support, and research for the prevention,
More informationHBV DNA < monitoring interferon Rx
Hepatitis B Virus Suspected acute hepatitis >>Order: Acute Unknown hepatitis screen Suspected chronic hepatitis >>Order: Chronic unknown hepatitis screen Acute HBV or Delayed Anti HBs response after acute
More informationThe Hepatitis B virus (HBV)
The Hepatitis B virus (HBV) There are 400 million people in the world who live with chronic hepatitis B, including France. Most people don t even know they are infected. But there are several important
More informationLancet Device Incident Investigation Report - 2012
Lancet Device Incident Investigation Report - 2012 Summary On May 16, 2012 the Winnipeg Regional Health Authority (WRHA) received notification from the University of Manitoba (U of M) of an incident at
More informationTESTING AND MANAGEMENT. Dr Nicole Allard GP Cohealth, Joslin Clinic, West Footscray PhD student, Epidemiology Unit VIDRL
TESTING AND MANAGEMENT Dr Nicole Allard GP Cohealth, Joslin Clinic, West Footscray PhD student, Epidemiology Unit VIDRL Disclosure and acknowledgments No conflicts of interest Board Member of Hepatitis
More informationNew York Hepatitis C Research Consortium September 29, 2014
New York Hepatitis C Research Consortium September 29, 2014 Dear Fellow Researcher, The Planning Committee would like to invite you to join us for the 2014 Meeting of the New York Hepatitis C (HCV) Research
More informationTravel Medicine 2016. Travel Medicine Vaccines & Therapeutics. Brochure. International Conference on. Travel Medicine 2016
International Conference on Travel Medicine Vaccines & Therapeutics New Orleans, USA August 01-02, 2016 Brochure Conference Secretariat 2360 Corporate Circle, Suite 400, Henderson, NV 89074-7722, USA Ph:
More informationHing wars. During World War II, there was a series of hepatitis outbreaks
Hepatitis C: Toward a Cure and Eradication 1 CHARLES M. RICE Head, Laboratory of Virology and Infectious Disease Scientific and Executive Director Center for the Study of Hepatitis C Rockefeller University
More informationUpdate on Hepatitis C. Sally Williams MD
Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;
More informationNational Health Burden of CLD in Italy
National Health Burden of CLD in Italy 11,000 deaths due to liver cirrhosis or HCC in 2006 Direct costs for the National Health System for treating CLD patients: 420 M / year for hospital care 164 M /
More informationHBV Treatment Guidelines. By: Prof.Dr. Abdelfatah Hanno Professor of Tropical Medicine Alexandria Faculty of Medicine
HBV Treatment Guidelines By: Prof.Dr. Abdelfatah Hanno Professor of Tropical Medicine Alexandria Faculty of Medicine A 29 Y old lady diagnosed as chronic HBV 3 years ago during her pregnancy, no treatment
More informationFocus on Transplantation: Treatment Post-transplant for HBV and HCV
Focus on Transplantation: Treatment Post-transplant for HBV and HCV The Viral Hepatitis Congress, Frankfurt, 09. September 2012 Christoph Sarrazin J. W. Goethe-University Hospital Medizinische Klinik I
More informationA Proposal for Managing the Harvoni Wave June 22, 2015
A Proposal for Managing the Harvoni Wave June 22, 2015 Clinical Background Hepatitis C is an infectious disease caused by the Hepatitis C Virus (HCV) that damages the liver over time. The disease affects
More informationPROGRAMME SPECIFICATION
PROGRAMME SPECIFICATION Awarding body/institution: Queen Mary, University of London Teaching institution (if different from above): Centre for Infectious Disease, Institute of Cell and Molecular Science,
More informationLiver Disease and Therapy of Hepatitis B Virus Infections
Liver Disease and Therapy of Hepatitis B Virus Infections University of Adelaide Catherine Scougall Arend Grosse Huey-Chi Low Allison Jilbert Fox Chase Cancer Center Chunxiao Xu Carol Aldrich Sam Litwin
More informationInfection with the hepatitis B virus
Obstetrics Report Chronic Hepatitis B in Pregnancy A Workshop Consensus Statement on Screening, Evaluation, and Management, Part 1 Joseph Apuzzio, MD; Joan M. Block, RN, BSN; Samuel Cullison, MD; Chari
More informationOptimising therapy in chronic hepatitis B: Switch or add treatment
Optimising therapy in chronic hepatitis B: Switch or add treatment Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University,Thailand NA + NA Percent with resistance
More informationLong-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B
Long-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B Patrick Marcellin Viral Hepatitis Research Center Hôpital Beaujon, University of Paris France OBJECTIVES OF THERAPY IN CHRONIC
More informationThe availability of newer antiviral agents, as
TREATMENT OF HEPATITIS B VIRUS INFECTION * Norman L. Sussman, MD ABSTRACT In treating chronic hepatitis B virus (HBV) infection, the primary goal of therapy is to achieve sustained suppression of HBV replication,
More informationTG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS
TG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS Karine Lélu 1, Alexei Evlachev 1, Roland Kratzer 1, Sarah
More informationAssessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C
Department of Veterans Affairs Health Services Research & Development Service Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C March 2013 Prepared for: Department of Veterans
More informationHCV RNA Monitoring System Meets Critical Need to Monitor Patient Viral Loads in Hepatitis C Virus (HCV) Clinical Trials
HCV RNA Monitoring System Meets Critical Need to Monitor Patient Viral Loads in Hepatitis C Virus (HCV) Clinical Trials Stephanie F. Finn, MS; John P. MacNeela, MSPH; Rebecca Wilgus RN, MSN; Amanda L.
More information1.1.2 Amend the that the Special Authority relating to tenofovir for use in pregnancy for postpartum care;
Anti-Infective Subcommittee of PTAC Meeting held 1 March 2012 (minutes for web publishing) Anti-Infective Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationGenomic Medicine Education Initiatives of the College of American Pathologists
Genomic Medicine Education Initiatives of the College of American Pathologists Debra G.B. Leonard, MD, PhD, FCAP Chair, Personalized Healthcare Committee, CAP Professor of Pathology, Weill Cornell Medical
More informationOptimal therapy for chronic hepatitis B: hepatitis B virus combination therapy?
Liver International ISSN 1478-3223 REVIEW ARTICLE Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy? Jorg Petersen 1 and Maura Dandri 2 1 IFI Institute at the Asklepios Klinik
More informationChronic hepatitis B (CHB) remains an important public SPECIAL REPORT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1315 1341 SPECIAL REPORT A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update EMMET B. KEEFFE,*
More informationHepatitis B. What I need to know about. National Digestive Diseases Information Clearinghouse NATIONAL INSTITUTES OF HEALTH
What I need to know about Hepatitis B U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH National Digestive Diseases Information Clearinghouse What I need to know about Hepatitis
More informationInstitute of International Business Relations. Less theory more focus on application
Institute of International Business Relations Less theory more focus on application IBR Institute of International Business Relations Stay ahead join IBR IBR Institute of International Business Relations
More informationD Candotti. Institut National de la Transfusion Sanguine Dept. Agents Transmissibles par le Sang Paris, France
Molecular characterization of hepatitis B virus strains infecting blood donors with high HBsAg and undetectable HBV DNA levels: implications for blood safety and screening policy D Candotti Institut National
More information13 September 2016 - London, UK
INTERNATIONAL WORKSHOP PRELIMINARY PROGRAMME MS Academia: Multiple sclerosis advanced course 13 September 2016 - London, UK MS Academia - Multiple sclerosis advanced course Overview Multiple sclerosis
More informationJUNE 2-3, 2014 CONNECT.
JUNE 2-3, 2014 CONNECT. GROW. SUCCEED. THIRD INDUSTRIAL CELL CULTURE TECHNOLOGY CONFERENCE JUNE 2-3, 2014 Laupheim s historical castle, Schloss Großlaupheim, Germany Rentschler Biotechnologie GmbH is delighted
More informationTreatment of Hepatitis B
Treatment of Hepatitis B Paul Y Kwo, MD Professor of Medicine Gastroenterology/Hepatology Division Medical Director, Liver Transplantation Indiana University Health Indiana University School of Medicine
More informationSIXTY-SEVENTH WORLD HEALTH ASSEMBLY. Agenda item 12.3 24 May 2014. Hepatitis
SIXTY-SEVENTH WORLD HEALTH ASSEMBLY WHA67.6 Agenda item 12.3 24 May 2014 Hepatitis The Sixty-seventh World Health Assembly, Having considered the report on hepatitis; 1 Reaffirming resolution WHA63.18,
More information2016 ISONG World Congress
2016 ISONG World Congress Sponsor and Exhibitor Prospectus Integrating Genetics Across Nursing Practice August 4-6, 2016 Royal Marine Hotel Dublin, Ireland JOIN US! Be recognized as an industry leader
More informationHepatitis B and C What Is New In Perinatal Transmission?
Hepatitis B and C What Is New In Perinatal Transmission? Claudia M Espinosa, MD, MSc Pediatric Infectious Diseases University of Louisville July 28, 2015 Disclosure Statement I am a principal investigator
More informationHepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL
Hepatitis C Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Recent Advances in Hepatitis C Appreciation that many patients are undiagnosed Improved screening to identify infected persons Assessment
More informationHepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total
Hepatitis Update Jürgen Rockstroh, MD Study 11: SVR at post-treatment week 24 (SVR24) Patients with Undetectable HCV RNA (Percentage) 8 7 6 5 4 3 2 1 71 No ART EFV/TDF/FTC ART/r/TDF/FTC Total 69 8 74 n/n
More informationPatients with HCV and F1 and F2 fibrosis stage: treat now or wait?
Liver International ISSN 1478-3223 REVIEW ARTICLE Patients with HCV and F1 and F2 fibrosis stage: treat now or wait? Mitchell L. Shiffman 1 and Yves Benhamou 2 1 Liver Institute of Virginia, Bon Secours
More informationHepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS
Hepatitis B and C Co-infection Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Objectives Review natural history of hepatitis coinfection Brief overview of treatment indications for
More informationNEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15)
NEW DRUGS FOR THE TREATMENT OF HEPATITIS C Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) Objectives Determine initial treatment options for patients with
More informationTreatment Strategies of Hepatitis B in China
Treatment Strategies of Hepatitis B in China Guangbi Yao MD Shanghai Jing-An Qu Central Hospital 200040 Characteristic features of CHB in China Huge amount of patients Infection during early life Maternal
More informationThe Immune System and Disease
Chapter 40 The Immune System and Disease Section 40 1 Infectious Disease (pages 1029 1033) This section describes the causes of disease and explains how infectious diseases are transmitted Introduction
More informationMEDICAL POLICY STATEMENT
MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 5/21/2014 3/24/2016 3/24/2015 Policy Name Policy Number Hepatitis C Oral SRx-0003 Medical Policy Statements
More informationEASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection European Association for the Study of the Liver Introduction Our understanding of the natural history of hepatitis B
More informationHepatitis B: Objectives. Hepatitis C: Objectives. Hepatitis B: Natural History. Hepatitis B is a DNA virus and is NOT curable.
Two Silent Epidemics - Chronic Hepatitis B and Hepatitis C: A Primer for Primary Care Practitioners Rebekah Hamner, MA, MSN, APRN, AGCNS Austin Hepatitis Center Dr. Imtiaz Alam 1/25/15 Hepatitis B: Objectives
More informationAcute HCV was defined as (3 out of 4 within the preceding 4 months):
Christoph Boesecke, Patrick Ingiliz, Hans-Jürgen Stellbrink, Mark Nelson, Sanjay Bhagani, Marguerite Guiguet, Marc-Antoine Valantin, Thomas Reiberger, Martin Vogel, Jürgen K. Rockstroh, and the NEAT study
More informationAdvanced Management Issues in HIV Medicine
Is a Cure Possible for HIV? Department of Infectious Disease and R.J. Fasenmyer Center for Clinical Immunology 6th Annual Advanced Management Issues in HIV Medicine May 30 31, 2013 InterContinental Hotel
More informationICS Summer School 2016
ICS Summer School 2016 Scientific Trends at the Interfaces Scientific Visualization Data Science Organisers: Pascal Frey, Patrick Gallinari, Agathe Guilloux, Sylvie Thiria, Julien Tierny July 18th August
More informationLA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova
LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova HBV ed HCV Due virus Diversi ma con molte Cose in Comune
More informationHepatitis C Treatment For Injecting Drugs
UPDATED 15. 5. 2015 PERSPECTIVES ON DRUGS Hepatitis C treatment for injecting drug users Transmitted through the sharing of needles, syringes and other injecting equipment, hepatitis C is the most common
More informationGenetic testing. The difference diagnostics can make. The British In Vitro Diagnostics Association
6 Genetic testing The difference diagnostics can make The British In Vitro Diagnostics Association Genetic INTRODUCTION testing The Department of Health published Our Inheritance, Our Future - Realising
More informationI wish you an inspiring and successful learning experience here in Saint Petersburg. Yours Sincerely, Rachel Clark CEO, EXCEMED
Dear participant, A warm welcome to the "Advanced worshop in Embriology" event. I would like to inform you that as of 28 April 2014 the name of our Foundation changed to EXCEMED Excellence in Medical Education.
More informationCoinfezione HIV-HCV. Raffaele Bruno, MD. Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Coinfezione HIV-HCV Raffaele Bruno, MD This program is supported by educational grants from Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
More information12 TH ALL-OHIO INSTITUTE ON COMMUNITY PSYCHIATRY
12 TH ALL-OHIO INSTITUTE ON COMMUNITY PSYCHIATRY INTEGRATING CARE: PREPARING YOUR WORKFORCE FOR THE FUTURE MARCH 27 28, 2015 DoubleTree by Hilton Cleveland East Beachwood 3663 Park East Drive, Beachwood,
More informationStepwise Approach for Detecting, Evaluating, and Treating Chronic Hepatitis B Virus Infection
Stepwise Approach for Detecting, Evaluating, and Treating Chronic Hepatitis B Virus Infection Federal Bureau of Prisons Clinical Practice Guidelines January 20, 2011 Clinical guidelines are made available
More informationHepatitis C Virus Infection in Massachusetts: A tale of two epidemics
Hepatitis C Virus Infection in Massachusetts: A tale of two epidemics Daniel Church, MPH Massachusetts Department of Public Health Bureau of Infectious Disease 1 Goals of presentation Provide an overview
More informationUCLA Asian Liver Program
CLA Program Update Program Faculty Myron J. Tong, PhD, MD Professor of Medicine Hepatology Director, Asian Liver Program Surgery Ronald W. Busuttil, MD, PhD Executive Chair Department of Surgery Director,
More informationHepatitis B Virus Program
Hepatitis B Virus Program Abstract Hepatitis B is a viral hepatitis representing a major global health problem. According to the World Health Organization (WHO), some 360 million people, or 5% of the world
More informationboceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationPRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT
PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON
More informationagenda 11 13 March 2015 Prague, Czech Republic
agenda 11 13 March 2015 Prague, Czech Republic Welcome Agenda Dear Colleague, As chairmen of the scientific committee, we are delighted to welcome you to the historic city of Prague for the Obstetrics
More informationPerspective Advances in the Treatment of Hepatitis C Virus Infection
Advances in HCV Treatment Volume 20 Issue 1 April/May 2012 Perspective Advances in the Treatment of Hepatitis C Virus Infection Since 2007, the annual age-adjusted mortality rate in hepatitis C virus (HCV)
More informationObjectives. Hepatitis C: The new era of screening and treatment. Distribution of HCV genotypes 11/1/2014. History of HCV diagnosis and screening
Objectives Hepatitis C: The new era of screening and treatment David Crabb, M.D. Department of Medicine, Indiana University and Eskenazi Health Describe the natural history of HCV infection Be able to
More information4 About FameLab. 7 Chair of the Jury. 7 Jury Members
-1- - 2 - Table of Content 4 About FameLab 5 Programme 6 Moderator 7 Chair of the Jury 7 Jury Members - 3 - About FameLab FameLab aims to discover charismatic, up-and-coming scientists who inspire people
More informationROYAL HOSPITAL FOR WOMEN
HEPATITIS B POSITIVE MOTHERS AND THEIR BABIES This LOP is developed to guide clinical practice at the Royal Hospital for Women. Individual patient circumstances may mean that practice diverges from this
More informationEmotion, behaviour and applied psychology in diabetes education
Emotion, behaviour and applied psychology in diabetes education ADEA Thought Leadership Lecture series supported by 1 ADEA would like to appreciate the support of our partner universities This program
More informationRibavirin/Pegylated Interferon Combination Therapy for People with Hepatitis C
Ribavirin/Pegylated Combination Therapy for People with Hepatitis C 1. Introduction 2. What the treatment does 3. When to take it 4. What is? 5. What is interferon? 6. What is pegylated interferon? 7.
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationMay 28-30, 2015 Ghent, Belgium Venue: het Pand
Sponsorship Opportunities The Abdominal Compartment Society 7th World Congress of the Abdominal Compartment Society May 28-30, 2015 Ghent, Belgium Venue: het Pand @WSACS www.wsacs.org The Abdominal Compartment
More informationEnter this essay in the English Language Learner (for 5 years or less of English) category: _X_ Yes
Date: 2/24/2015 Student Name: Nikita Skiba Title of Essay: HIV/AIDS treatments Teacher s Name: Cheryl McClure School Name: International School School Address: 445 128th Ave SE Bellevue WA 98005 Enter
More informationMonitoring of Treatment of viral hepatitis C
Monitoring of Treatment of viral hepatitis C J.Boubaker Department of Gastroenterology La Rabta hospital Tunis-Tunisia Monitoring of Hepatitis C Treatment Aims of Monitoring : Evaluate Efficacy. Detect
More informationThis international event will discuss new cellular, molecular and chemical approaches to improving immunisation efficacy.
This international event will discuss new cellular, molecular and chemical approaches to improving immunisation efficacy. This event has CPD accreditation www.lifescienceevents.com/vaccine2016 #VaccineESC
More informationCASG HBV Study Richard B. Pollard, MD David M. Asmuth, MD Division of Infectious Diseases University of California Davis Medical Center Sacramento, CA
CASG HBV Study Richard B. Pollard, MD David M. Asmuth, MD Division of Infectious Diseases University of California Davis Medical Center Sacramento, CA Characteristics of HBV DNA Hepadnavirus Reverse transcriptase
More information3.0 Treatment of Infection
3.0 Treatment of Infection Antibiotics and Medicine National Curriculum Link SCN 3-13b SCN 3-20b HWB 3-15a HWB 3-16a HWB 3-17a Learning Outcomes All students will know: Most common infections will get
More informationPeg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence
More informationCongress Theme: Global Event: Regionally Aligned: Educational Value: Committed:
About WCN ISN s biennial World Congress of Nephrology (WCN) is the premiere educational event in nephrology which rotates between continents and is organized in collaboration with local and regional nephrology
More information